Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
HLA-A*02:01 is a highly prevalent allele of the HLA class I histocompatibility antigen, A alpha chain (HLA-A), which plays a critical role in the adaptive immune system. It forms a heterotrimeric complex with beta-2 microglobulin and intracellularly derived peptide antigens, presenting them on the cell surface for recognition by CD8-positive cytotoxic T cells. In oncology, HLA-A*02:01 is a pivotal therapeutic target because it presents tumor-associated antigens (such as gp100 and MAGE-A4) that can be targeted by engineered T-cell receptors (TCRs) and bispecific T-cell engagers. Drugs like tebentafusp (Kimmtrak) and afamitresgene autoleucel (Tecelra) are specifically designed to bind to these peptide-HLA-A*02:01 complexes, bridging cancer cells with T cells to induce tumor lysis. However, because HLA-A*02:01 expression varies significantly across ethnic populations, therapies restricted to this allele face challenges regarding equitable patient access. Additionally, therapeutic targeting of this complex is associated with safety concerns such as cytokine release syndrome and on-target, off-tumor toxicities in normal tissues expressing the target antigen.
Bispecific T-cell engager (ImmTAC) that redirects CD3+ T cells to target gp100 peptide presented by HLA-A*02:01; T-cell receptor (TCR) engineered T-cell therapy targeting MAGE-A4 peptide presented by HLA-A*02:01
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on HLA class I histocompatibility antigen, A alpha chain (HLA-A*02:01) (HLA-A*02:01).